This Core component of the program project will be responsible for collection, management and analysis of all the data that will be collected to meet the aims of the Program. A team has been assembled who have the expertise to maintain and upgrade the data management systems so that data are efficiently recorded and checked for completion and internal consistency and to provide appropriate statistical analyses. By planning from data entry to statistical analysis, we can ensure that the data are collected and processed in an appropriate and efficient manner. Our databases will merge data from different sources (clinical data and several laboratories) and provide statistical analyses of such data sets. We maintain accurate documentation of the organization and detailed codes of the database and statistical codes. We will work closely with the Clinical Core to identify any missing data in a timely fashion. The staff of this core will participate in the design of all investigations that arise in the course of this program project, from analysis methods and power calculations to forms and database design. This core will provide periodic status reports to the Clinical and Administrative Cores, and will work closely with the staff of each project to see that the data are analyzed appropriately and the analyses are clearly documented. We will program recurring analyses, so that routine re-analysis and updates will be accurate re-analysis. We will participate in preparation of papers, being responsible for the statistical analyses, statistical graphs, and descriptions of the statistical methods.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA075606-05
Application #
6459010
Study Section
Project Start
2001-06-07
Project End
2003-05-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
5
Fiscal Year
2001
Total Cost
$312,755
Indirect Cost
Name
Rush University Medical Center
Department
Type
DUNS #
City
Chicago
State
IL
Country
United States
Zip Code
60612
Raza, A; Candoni, A; Khan, U et al. (2004) Remicade as TNF suppressor in patients with myelodysplastic syndromes. Leuk Lymphoma 45:2099-104
Candoni, Anna; Silvestri, Federico; Buonamici, Silvia et al. (2004) Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol 41:13-20
Raza, Azra; Buonamici, Silvia; Lisak, Laurie et al. (2004) Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res 28:791-803
Huang, X K; Meyer, P; Li, B et al. (2003) The effects of the farnesyl transferase inhibitor FTI L-778,123 on normal, myelodysplastic, and myeloid leukemia bone marrow progenitor proliferation in vitro. Leuk Lymphoma 44:157-64
Gladstone, Betty; Sivaraman, Smitha; Galili, Naomi et al. (2003) A novel method for single cell detection of in situ telomerase or histone H3 in combination with clonal analysis by FISH. Leuk Res 27:529-37
Reddy, Poluru L; Shetty, Vilasini T; Dutt, Diya et al. (2002) Increased incidence of mitochondrial cytochrome c-oxidase gene mutations in patients with myelodysplastic syndromes. Br J Haematol 116:564-75
Allampallam, Krishnan; Shetty, Vilasini; Mundle, Suneel et al. (2002) Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. Int J Hematol 75:289-97
Shetty, Vilasini; Hussaini, Seema; Alvi, Sairah et al. (2002) Excessive apoptosis, increased phagocytosis, nuclear inclusion bodies and cylindrical confronting cisternae in bone marrow biopsies of myelodysplastic syndrome patients. Br J Haematol 116:817-25
Zorat, F; Shetty, V; Dutt, D et al. (2001) The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol 115:881-94
Preisler, H D (2001) Evolution of secondary hematologic disorders: preMDS-->MDS-->sAML. Cancer Treat Res 108:185-230

Showing the most recent 10 out of 40 publications